Inflation Fears Send SunOpta, Tilray, Olaplex, Energizer, and Hain Celestial Stocks Plummeting

Several stocks, including SunOpta, Tilray, Olaplex, Energizer, and Hain Celestial, plummeted after inflation data showed higher-than-expected wholesale prices, potentially squeezing profit margins and reducing the likelihood of the Federal Reserve cutting interest rates. The stock market overreacts to news, and these price drops present good buying opportunities for high-quality stocks.

July 02, 2025

Several stocks, including SunOpta, Tilray, Olaplex, Energizer, and Hain Celestial, experienced significant declines on July 2, 2025, following the release of higher-than-expected inflation data. The afternoon session saw markets pull back amid concerns over rising wholesale prices, as indicated by the July Producer Price Index (PPI). The higher-than-expected reading suggests that companies may face squeezed profit margins due to increasing costs, thereby reducing the likelihood of the Federal Reserve cutting interest rates and potentially dampening economic activity. Additionally, reports of a weakening consumer further compounded these inflation fears.

Among the impacted stocks, SunOpta (NASDAQ: STKL) fell by 3%, Tilray (NASDAQ: TLRY) dropped by 6.4%, Olaplex (NASDAQ: OLPX) fell by 3.8%, Energizer (NYSE: ENR) declined by 4.9%, and Hain Celestial (NASDAQ: HAIN) fell by 3.2%. These price drops present potential buying opportunities for investors looking to acquire high-quality stocks at more favorable prices.

Tilray's shares, known for their volatility, experienced a 61-move greater than 5% over the past year. Today's decline indicates that the market considers the latest news meaningful but not a fundamental change in the company's business outlook. The previous significant move for Tilray occurred just one day prior, when the stock gained 18.9% on the announcement of a strategic partnership to expand its medical cannabis presence in Italy. This partnership, between Tilray's subsidiary FL Group and Italian pharmaceutical firm Molteni, aims to increase the availability of Tilray's medical cannabis extracts across Italy. Additionally, Tilray's stock has benefited from a sector-wide rally fueled by optimism over potential U.S. regulatory changes that could reclassify marijuana from a Schedule I to a Schedule III substance. This potential shift could provide significant tax relief for cannabis companies by easing restrictions under Internal Revenue Code Section 280E, directly improving profitability.

Despite recent volatility, Tilray remains down 20.5% since the beginning of the year and is trading at $1.16 per share, 40.5% below its 52-week high of $1.95 from August 2024.

References:
[1] https://stockstory.org/us/stocks/nasdaq/stkl/news/why-up-down/sunopta-tilray-olaplex-energizer-and-hain-celestial-shares-plummet-what-you-need-to-know
[2] https://finance.yahoo.com/news/sunopta-tilray-olaplex-energizer-hain-203540447.html
[3] https://www.ainvest.com/news/tilray-stock-price-explodes-trump-proposal-reclassify-marijuana-dangerous-2508/